Burney Co. Decreases Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

Burney Co. decreased its position in United Therapeutics Co. (NASDAQ:UTHR) by 28.9% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 15,966 shares of the biotechnology company’s stock after selling 6,483 shares during the quarter. Burney Co.’s holdings in United Therapeutics were worth $5,086,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of UTHR. V Square Quantitative Management LLC purchased a new stake in United Therapeutics in the 2nd quarter valued at about $30,000. Rise Advisors LLC bought a new stake in shares of United Therapeutics in the 1st quarter valued at about $32,000. GAMMA Investing LLC purchased a new stake in shares of United Therapeutics in the 4th quarter worth approximately $43,000. Benjamin F. Edwards & Company Inc. raised its position in shares of United Therapeutics by 63.6% in the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock worth $69,000 after acquiring an additional 117 shares in the last quarter. Finally, Janiczek Wealth Management LLC lifted its position in shares of United Therapeutics by 21.1% during the first quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock valued at $111,000 after buying an additional 84 shares during the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other United Therapeutics news, Director Raymond Dwek sold 5,000 shares of the stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $325.35, for a total value of $1,626,750.00. Following the sale, the director now directly owns 1,750 shares of the company’s stock, valued at approximately $569,362.50. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, Director Nilda Mesa sold 266 shares of the company’s stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $318.58, for a total value of $84,742.28. Following the completion of the sale, the director now directly owns 5,107 shares of the company’s stock, valued at $1,626,988.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Raymond Dwek sold 5,000 shares of the stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $325.35, for a total value of $1,626,750.00. Following the sale, the director now directly owns 1,750 shares of the company’s stock, valued at $569,362.50. The disclosure for this sale can be found here. In the last three months, insiders have sold 118,935 shares of company stock valued at $37,729,687. Company insiders own 12.50% of the company’s stock.

United Therapeutics Price Performance

NASDAQ UTHR traded up $0.61 during mid-day trading on Thursday, hitting $360.45. The stock had a trading volume of 129,791 shares, compared to its average volume of 493,970. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $365.98. The stock has a market capitalization of $15.99 billion, a price-to-earnings ratio of 17.25, a PEG ratio of 1.25 and a beta of 0.55. The firm’s 50 day moving average is $328.40 and its 200 day moving average is $276.41. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.35 and a quick ratio of 4.18.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The company had revenue of $714.90 million during the quarter, compared to analysts’ expectations of $691.87 million. During the same quarter last year, the company earned $5.24 earnings per share. United Therapeutics’s revenue for the quarter was up 19.8% on a year-over-year basis. Equities research analysts forecast that United Therapeutics Co. will post 24.86 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on UTHR. JPMorgan Chase & Co. lifted their price target on shares of United Therapeutics from $280.00 to $300.00 and gave the stock an “overweight” rating in a report on Tuesday, May 21st. LADENBURG THALM/SH SH lowered shares of United Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 1st. Wells Fargo & Company lifted their price objective on shares of United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 20th. HC Wainwright restated a “buy” rating and issued a $400.00 target price on shares of United Therapeutics in a research note on Thursday, August 1st. Finally, Bank of America reduced their price objective on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a research note on Thursday, August 1st. One analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have issued a buy rating to the company. According to MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $350.36.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.